# Pyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER2-positive Early Breast Cancer

> **NCT06537674** · — · NOT_YET_RECRUITING · sponsor: **Jiangsu Famous Medical Technology Co., Ltd.** · enrollment: 100 (estimated)

## Conditions studied

- HER2+ Breast Cancer

## Interventions

- **DRUG:** Trastuzumab intravenous drip/Trastuzumab Subcutaneous Injection

## Key facts

- **NCT ID:** NCT06537674
- **Lead sponsor:** Jiangsu Famous Medical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-08-15
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06537674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06537674, "Pyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER2-positive Early Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06537674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*